Blog

IBS-C Requires a Distinct Treatment Approach in Overactive Bladder Comorbidity A 2026 study of 144 patients at China’s Nanfang Hospital reveals that con…

Introduction A one-size-fits-all approach to treating irritable bowel syndrome with constipation (IBS-C) often leads to disappointing results

Decoding Depression: How Gut Bacteria and Adversity Shape the Adolescent Brain New research from the University of California, Los Angeles proposes a di…

Psychobiotics: The Mental Health Probiotics Targeting Your Gut-Brain Axis The brain uses γ-aminobutyric acid (GABA), its main inhibitory neurotransmitte…

The Teen Bugs Study: Tracking Early Trauma, Gut Bacteria, and Depression Risk in Adolescents Researchers at the University of California, Los Angeles, h…

IBS-C Constipation Treatment Management: Why One-Size-Fits-All Fails Irritable bowel syndrome with constipation presents a complex clinical picture, oft…

GABA-Producing Gut Bacteria Are Emerging as a New Class of Psychobiotics A 2026 review from the Prof

Psychobiotics and Mental Health: The Evidence for GABA-Producing Gut Bacteria Gut bacteria in the genera Lactobacillus , Bifidobacterium , and Bacteroid…

The Gut-Brain Axis in Depression: A Pathway from Early Trauma to Reward Dysfunction The conversation about depression is expanding beyond neurotransmitt…

IBS-C is a Mechanistically Distinct Phenotype, Not a One-Size-Fits-All Condition Irritable bowel syndrome with constipation affects up to 35% of IBS pat…

Psychobiotics: A New Frontier in Mental Health Through the Gut A 2026 review published in the International Journal of Molecular Sciences consolidates e…

IBS-C and OAB: A Distinct Subtype That Defies One-Size-Fits-All Treatment New research from Southern Medical University suggests a standard treatment pr…